| Value | ₹120.8 Cr |
|---|---|
| Order from | HarmeeCare Pharmaceuticals |
BSE filing, NSE: KILITCH. Summary written from the filing by ALFA Finder's alert engine.
Kilitch Drugs(I) Ltd: key numbers
- Share price
- ₹214.97
- Market cap
- ₹751.6 Cr
- Revenue (annual)
- ₹235.5 Cr
- Net profit (annual)
- ₹30.17 Cr
- P/E (TTM)
- 25.0×Sector 46.1×
- Promoter holding
- 63.77%+0.00% QoQ
- FII holding
- 0.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kilitch Drugs(I) Ltd
All →Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs' EGM notice seeks shareholder approval for selling its Ethiopian material subsidiary and converting subsidiary debt into equity. It also proposes two independent director appointments.
Kilitch Drugs(I) Merger & Restructuring Worth ₹131.6 Cr
Kilitch Drugs will divest its entire Ethiopian subsidiary stake to HarmeeCare for US$14 million (~₹131.6 Crore). Proceeds will fund debt repayment and Pen plant expansion.
- Value
- ₹131.6 Cr
Kilitch Drugs(I) Management Change
Kilitch Drugs' Non-Executive Independent Director Mr. Venkita Subramanian Rajan resigned effective 21 Oct 2026. He also stepped down from the Audit, NCR, and SRC Committees citing personal commitments.
Kilitch Drugs(I) Other Announcement
Kilitch Drugs (India) Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026.
Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs (India) held its 34th Annual General Meeting on August 27, 2026, transacting four business resolutions including financial statement approval and director re-appointment.
Kilitch Drugs(I) Other Announcement
Kilitch Drugs filed its Monitoring Agency Report for the quarter ended June 30, 2026, concerning its Rights Issue proceeds of Rs. 49.92 Crore.
- Value
- ₹49.92 Cr
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr